Krystal Biotech Inc (KRYS)vsEli Lilly and Company (LLY)
KRYS
Krystal Biotech Inc
$305.71
+3.04%
HEALTHCARE · Cap: $8.75B
LLY
Eli Lilly and Company
$948.45
-2.72%
HEALTHCARE · Cap: $869.41B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 17213% more annual revenue ($72.25B vs $417.30M). KRYS leads profitability with a 53.9% profit margin vs 35.0%. LLY trades at a lower P/E of 34.7x. LLY earns a higher WallStSmart Score of 78/100 (B+).
KRYS
Buy65
out of 100
Grade: C+
LLY
Strong Buy78
out of 100
Grade: B+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 54 of every $100 in revenue as profit
Strong operational efficiency at 46.1%
Revenue surging 31.9% year-over-year
Earnings expanding 52.5% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Mega-cap, among the largest globally
Every $100 of equity generates 108 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Areas to Watch
Premium valuation, high expectations priced in
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 27.2x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : KRYS
The strongest argument for KRYS centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 53.9% and operating margin at 46.1%. Revenue growth of 31.9% demonstrates continued momentum.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bear Case : KRYS
The primary concerns for KRYS are P/E Ratio.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Key Dynamics to Monitor
KRYS carries more volatility with a beta of 0.49 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (78/100 vs 65/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Krystal Biotech Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Krystal Biotech, Inc., a clinical-stage biotechnology company, is dedicated to the field of redosable gene therapy to treat serious rare diseases in the United States. The company is headquartered in Pittsburgh, Pennsylvania.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?